
-
Battered Myanmar scam centre workers wait for deportation to China
-
Niger turns to satellites to bridge digital divide
-
Refugees revive village in 'empty Spain'
-
Eddie Jones hails Japan 'tour of a lifetime' with Wales, Ireland games
-
Blinded Ukrainian soldiers face new challenges at home
-
Philips losses worse than expected in 2024
-
EU eyes stricter food import rules in agriculture policy review
-
Pragmatic Italy in good place before hosting France: Azzurri great Dominguez
-
New arena, new attitudes? Cash spat in spotlight at UN nature talks
-
Peru's 12-Angle Stone vandalized, causing 'irreversible damage'
-
WTA to ban man after Raducanu 'security incident' in Dubai
-
UN watchdog chief visits Fukushima as Japan returns to nuclear power
-
HSBC targets $1.5 bn in annual cost savings after revamp
-
UK military vets rebuild lives carving Viking longboat
-
After US election, Kremlin propagandist sets sights on German vote
-
US aid freeze stops crucial Pacific projects
-
Bolsonaro: Brazil's polarising ex-president mired in legal woes
-
Vietnam parliament approves $8 billion rail link to China
-
Asian markets swing as traders assess latest tariffs volley
-
Top South Korean judge faces disinformation deluge as Yoon impeachment looms
-
Rapper A$AP Rocky found not guilty in assault trial
-
Brazil prosecutor charges Bolsonaro over failed coup plot
-
US tariffs threat a 'shock' to Canadian businesses
-
US judge declines to block Musk from accessing data, firing workers
-
Mourinho eyes Europa League run with Fenerbahce
-
Pod of 157 dolphins stranded on remote Australian beach
-
Bayern's Kane says injury could keep him out against Frankfurt
-
Bayern edge out Celtic to reach Champions League last 16 as Milan are dumped out
-
Colombian president alleges plot to down his plane with missiles
-
Trump moves to widen IVF access, risking conservative fury
-
Doncic energizes LeBron as NBA homestretch begins
-
Bayern score late to see off Celtic in Champions League
-
China condemns US 'tariff shocks' at WTO
-
Club Brugge dump Atalanta out of Champions League
-
Formula One great Hamilton 'invigorated' by Ferrari move ahead of new season
-
France probes 2012 reporters' deaths in Syria as crime against humanity
-
Benfica hold off Monaco to reach Champions League last 16
-
England coach Borthwick has faith in 'world-class goal-kicker' Marcus Smith
-
More fireworks expected in emotional USA-Canada hockey rematch
-
F1 champion Verstappen expects Hamilton to be 'reborn' at Ferrari
-
Argentine appeals court throws out rape case against French rugbiers
-
Macron says Trump 'can restart useful dialogue' with Putin
-
Feyenoord knock out 10-man AC Milan to reach Champions League last 16
-
Verstappen says Red Bull resilience key to bid for fifth straight F1 title
-
'City killer' asteroid now has 3.1% chance of hitting Earth: NASA
-
LAFC star Giroud suffers home theft of $500,000 in jewelry: report
-
Berrettini ends Djokovic comeback at Qatar Open
-
Formula One chiefs plan changes to spice up Monaco Grand Prix
-
Ex-Springbok Rhule calls time on rugby career
-
Ireland and New Zealand return to Chicago in Autumn Series

Pfizer Q1 revenues jump 77% to $25.7 bn on Covid-19 vaccine
Pfizer reported another quarter of huge revenues growth because of its Covid-19 vaccine on Tuesday, but lowered the company's full-year profit forecast due in part to shifts in foreign exchange.
The major American drugmaker reported revenues of $25.7 billion for the first quarter, up 77 percent from the year-ago period, with the Covid vaccine taking in $13.2 billion.
Net income jumped 61 percent to $7.9 billion.
Pfizer confirmed its full-year revenues forecast, in which about just over half of total sales stem from the Covid-19 innoculation and from Paxlovid, the company's therapeutic to treat the coronavirus.
Pfizer, which has shipped some 3.4 billion doses of vaccine to 179 countries, has won regulatory approval for its shot in most age groups, but continues to study its use in children younger than five.
The company is also exploring "potential next-generation vaccines, including variant vaccines" for the fall season, Chief Executive Albert Bourla said in prepared remarks.
In the first quarter, Paxlovid took in $1.5 billion in global sales. But Pfizer expects 2022 sales of the medicine of $22 billion as it ramps up production and distribution.
The World Health Organization last month "strongly recommended" the antiviral pill Paxlovid for patients with milder forms of the disease who were still at a high risk of hospitalization.
But WHO said it was "extremely concerned" that low- and middle-income countries would be "pushed to the end of the queue" amid tight global supplies.
Pfizer now sees full-year adjusted profits of $6.25 to $6.45 a share, down 10 cents from the previous range.
The company attributed the lowered forecast to an accounting change in research and development expenses and to changes in the foreign exchange market that have seen the dollar rise compared with other major currencies.
Shares of Pfizer dipped 1.2 percent to $47.77 in pre-market trading.
L.Mesquita--PC